RVL Pharmaceuticals plc Annual Operating Income (Loss) in USD from 2017 to 2022

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
RVL Pharmaceuticals plc quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2022.
  • RVL Pharmaceuticals plc Operating Income (Loss) for the quarter ending June 30, 2023 was -$22M, a 45.6% decline year-over-year.
  • RVL Pharmaceuticals plc Operating Income (Loss) for the twelve months ending June 30, 2023 was -$70.8M, a 1.36% decline year-over-year.
  • RVL Pharmaceuticals plc annual Operating Income (Loss) for 2022 was -$59M, a 28.7% increase from 2021.
  • RVL Pharmaceuticals plc annual Operating Income (Loss) for 2021 was -$82.8M, a 8.71% increase from 2020.
  • RVL Pharmaceuticals plc annual Operating Income (Loss) for 2020 was -$90.7M, a 29% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$59M +$23.8M +28.7% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-20
2021 -$82.8M +$7.9M +8.71% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-20
2020 -$90.7M +$37.1M +29% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-30
2019 -$128M -$29.2M -29.7% Jan 1, 2019 Dec 31, 2019 8-K 2021-09-08
2018 -$98.5M -$46.5M -89.2% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-19
2017 -$52.1M Jan 1, 2017 Dec 31, 2017 8-K 2019-12-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.